- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Fund Finance
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- Innovation Protection
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Innovation Protection
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy Transition
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- Artificial Intelligence (AI) and Machine Learning
- Buy American
- Crisis Management
- Doing Business in Latin America
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
News 9 results
Cases & Deals
März 31, 2025
King & Spalding Secures Victory for The American Clinical Laboratory Association Challenging a Final Rule Issued by the FDA
Cases & Deals
November 17, 2022
Parallelimport von Arzneimitteln - King & Spalding vertritt Novartis vor dem EuGH
Cases & Deals
Juni 22, 2022
Cathay Capital Private Equity and 3i Enter into an Agreement to Sell Havea Group to BC Partners
Cases & Deals
Juli 20, 2016
King & Spalding Advises Jounce Therapeutics on Deal Worth Up to $2.5 Billion
Cases & Deals
März 24, 2016
King & Spalding Represents GSK on Strategic Collaboration with Miltenyi Biotec
Cases & Deals
September 17, 2015
King & Spalding Advises Nurix in $150 Million-Plus Drug Collaboration and Option Deal with Celgene
Cases & Deals
Juni 8, 2015
King & Spalding Team Advises Five Prime Therapeutics in $131 Million License Agreement with bluebird bio
Cases & Deals
Cases & Deals
Dezember 5, 2014
King & Spalding Advises Arbor Pharmaceuticals in Minority-Stake Sale to KKR